BCTXZ NASDAQ
BriaCell Therapeutics Corp. Warrant
1W: +86.7%
1M: +55.1%
3M: +222.2%
YTD: +18.4%
1Y: +39.8%
$0.30
+0.14 (+83.95%)
Weekly Expected Move ±49.4%
$0
$0
$0
$0
$1
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
26 relationships26
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2022-08-04
Earliest Filing
2026-01-15
Latest Filing
partner: 22
licensee: 2
customer: 1
supplier: 1
Counterparties (Filed by BCTXZ)
26 relationshipsCompanies named in BCTXZ's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Briacell Therapeutics Corp. | BCTXZ | partner | Company issuing securities in the offering | 2026-01-15 | View |
| ThinkEquity LLC | — | partner | Exclusive placement agent for the offering | 2026-01-15 | View |
| Computershare Inc. | — | partner | Warrant agent for the offering | 2026-01-15 | View |
| Computershare Trust Company, N.A. | — | partner | Wholly-owned subsidiary of Computershare Inc. acting as warrant agent | 2026-01-15 | View |
| Cozen O'Connor LLP | — | partner | Placement agent counsel handling closing | 2026-01-15 | View |
| MNP LLP | — | partner | Independent registered public accounting firm | 2026-01-15 | View |
| ThinkEquity LLC | — | partner | Exclusive placement agent for the offering | 2025-07-16 | View |
| Briacell Therapeutics Corp. | BCTXZ | partner | Company issuing securities in the offering | 2025-07-16 | View |
| BriaCell Therapeutics Corp. | BCTXZ | partner | Company issuing securities in the offering | 2025-04-28 | View |
| ThinkEquity LLC | — | partner | Representative of the several underwriters | 2025-04-28 | View |
| ThinkEquity LLC | — | partner | Exclusive placement agent for the offering | 2025-02-05 | View |
| Briacell Therapeutics Corp. | BCTXZ | partner | Company issuing shares in the offering | 2025-02-05 | View |
| BriaCell Therapeutics Corp. | BCTXZ | partner | Company issuing securities in an underwriting agreement | 2024-12-13 | View |
| ThinkEquity LLC | — | partner | Representative of the several underwriters | 2024-12-13 | View |
| ThinkEquity LLC | — | partner | Exclusive placement agent for the offering | 2024-10-02 | View |
| Briacell Therapeutics Corp. | BCTXZ | partner | Company issuing securities in the offering | 2024-10-02 | View |
| Briacell Therapeutics Corp. | BCTXZ | partner | Company issuing securities in the offering | 2024-09-12 | View |
| ThinkEquity LLC | — | partner | Exclusive placement agent for the offering | 2024-09-12 | View |
| BriaCell Therapeutics Corp. | BCTXZ | partner | Party to the Arrangement Agreement and Plan of Arrangement | 2023-05-31 | View |
| BriaPro Therapeutics Corp. | — | partner | Party to the Arrangement Agreement and Plan of Arrangement | 2023-05-31 | View |
| BriaCell Therapeutics Corp. (US) | BCTXZ | partner | Entity involved in the BriaCell Reorganization and intercompany debt | 2023-05-31 | View |
| Sapientia Pharmaceuticals Inc. | — | partner | Entity distributing Sapientia Assets to BriaCell U.S. | 2023-05-31 | View |
| BriaCell Therapeutics Corp. | BCTXZ | customer | Client utilizing Prevail's services for clinical trial management | 2023-05-15 | View |
| Prevail InfoWorks, Inc. | — | supplier | Provider of clinical research services and software platforms | 2023-05-15 | View |
| University of Maryland, Baltimore County | — | licensee | Licensor of patent rights for Soluble CD80 technology | 2022-08-04 | View |
| BriaCell Therapeutics Corp. | BCTXZ | licensee | Licensee granted exclusive rights to develop and commercialize Soluble CD80 technology | 2022-08-04 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-06-26 | Regulation FD; Exhibits | View | |
| 2026-06-03 | Material Agreement; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-03-31 | Regulation FD; Exhibits | View | |
| 2026-03-09 | Submission of Matters to a Vote of Security Holders | View | |
| 2026-02-20 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-15 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-12-29 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-12-01 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-08-26 | Other Events; Financial Statements and Exhibits | View | |
| 2025-07-16 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-06-18 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-04-28 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-03-12 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2025-02-13 | Other Events | View | |
| 2025-02-06 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-02-05 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Other Events; Fin | Agreement | View |
| 2025-01-28 | Other Events; Financial Statements and Exhibits | View | |
| 2025-01-03 | Other Events; Financial Statements and Exhibits | View | |
| 2025-01-03 | Other Events; Financial Statements and Exhibits | View | |
| 2024-12-16 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR